Folic Acid


Aphena Pharma Solutions - Tennessee, Llc
Human Prescription Drug
NDC 67544-989
Folic Acid is a human prescription drug labeled by 'Aphena Pharma Solutions - Tennessee, Llc'. National Drug Code (NDC) number for Folic Acid is 67544-989. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Folic Acid drug includes Folic Acid - 1 mg/1 . The currest status of Folic Acid drug is Active.

Drug Information:

Drug NDC: 67544-989
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Folic Acid
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Folic Acid
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Aphena Pharma Solutions - Tennessee, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:FOLIC ACID - 1 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Feb, 2016
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 22 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA204418
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Aphena Pharma Solutions - Tennessee, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:310410
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
UNII:935E97BOY8
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
67544-989-3030 TABLET in 1 BOTTLE, PLASTIC (67544-989-30)12 Jan, 2017N/ANo
67544-989-6090 TABLET in 1 BOTTLE (67544-989-60)24 May, 2017N/ANo
67544-989-65100 TABLET in 1 BOTTLE, PLASTIC (67544-989-65)20 Mar, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Folic acid folic acid folic acid folic acid lactose monohydrate cellulose, microcrystalline sodium starch glycolate type a potato stearic acid n;8

Drug Interactions:

Drug interactions there is evidence that the anticonvulsant action of phenytoin is antagonized by folic acid. a patient whose epilepsy is completely controlled by phenytoin may require increased doses to prevent convulsions if folic acid is given. folate deficiency may result from increased loss of folate, as in renal dialysis and/or interference with metabolism (e.g., folic acid antagonists such as methotrexate); the administration of anticonvulsants, such as diphenylhydantoin, primidone, and barbiturates; alcohol consumption and, especially, alcoholic cirrhosis; and the administration of pyrimethamine and nitrofurantoin. false low serum and red cell folate levels may occur if the patient has been taking antibiotics, such as tetracycline, which suppress the growth of lactobacillus casei .

Indications and Usage:

Indications and usage folic acid, usp is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid, usp (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood.

Warnings:

Warnings administration of folic acid alone is improper therapy for pernicious anemia and other megaloblastic anemias in which vitamin b 12 is deficient.

General Precautions:

General folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurologic manifestations remain progressive. there is a potential danger in administering folic acid to patients with undiagnosed anemia, since folic acid may obscure the diagnosis of pernicious anemia by alleviating the hematologic manifestations of the disease while allowing the neurologic complications to progress. this may result in severe nervous system damage before the correct diagnosis is made. adequate doses of vitamin b 12 may prevent, halt, or improve the neurologic changes caused by pernicious anemia.

Dosage and Administration:

Dosage and administration oral administration is preferred. although most patients with malabsorption cannot absorb food folates, they are able to absorb folic acid, usp given orally. parenteral administration is not advocated but may be necessary in some individuals (e.g., patients receiving parenteral or enteral alimentation). doses greater than 0.1 mg should not be used unless anemia due to vitamin b 12 deficiency has been ruled out or is being adequately treated with a cobalamin. daily doses greater than 1 mg do not enhance the hematologic effect, and most of the excess is excreted unchanged in the urine. the usual therapeutic dosage in adults and children (regardless of age) is up to 1 mg daily. resistant cases may require larger doses. when clinical symptoms have subsided and the blood picture has become normal, a daily maintenance level should be used, i.e., 0.1 mg for infants and up to 0.3 mg for children under 4 years of age, 0.4 mg for adults and children 4 or more years of a
ge, and 0.8 mg for pregnant and lactating women, but never less than 0.1 mg/day. patients should be kept under close supervision and adjustment of the maintenance level made if relapse appears imminent. in the presence of alcoholism, hemolytic anemia, anticonvulsant therapy, or chronic infection, the maintenance level may need to be increased.

Contraindications:

Contraindications folic acid, usp is contraindicated in patients who have shown previous intolerance to the drug.

Adverse Reactions:

Adverse reactions allergic sensitization has been reported following both oral and parenteral administration of folic acid. folic acid is relatively nontoxic in man. rare instances of allergic responses to folic acid preparations have been reported and have included erythema, skin rash, itching, general malaise, and respiratory difficulty due to bronchospasm. one patient experienced symptoms suggesting anaphylaxis following injection of the drug. gastrointestinal side effects, including anorexia, nausea, abdominal distention, flatulence, and a bitter or bad taste, have been reported in patients receiving 15 mg folic acid daily for 1 month. other side effects reported in patients receiving 15 mg daily include altered sleep patterns, difficulty in concentrating, irritability, overactivity, excitement, mental depression, confusion, and impaired judgment. decreased vitamin b 12 serum levels may occur in patients receiving prolonged folic acid therapy. in an uncontrolled study, orally admin
istered folic acid was reported to increase the incidence of seizures in some epileptic patients receiving phenobarbital, primidone, or diphenylhydantoin. another investigator reported decreased diphenylhydantoin serum levels in folate-deficient patients receiving diphenylhydantoin who were treated with 5 mg or 15 mg of folic acid daily.

Drug Interactions:

Drug interactions there is evidence that the anticonvulsant action of phenytoin is antagonized by folic acid. a patient whose epilepsy is completely controlled by phenytoin may require increased doses to prevent convulsions if folic acid is given. folate deficiency may result from increased loss of folate, as in renal dialysis and/or interference with metabolism (e.g., folic acid antagonists such as methotrexate); the administration of anticonvulsants, such as diphenylhydantoin, primidone, and barbiturates; alcohol consumption and, especially, alcoholic cirrhosis; and the administration of pyrimethamine and nitrofurantoin. false low serum and red cell folate levels may occur if the patient has been taking antibiotics, such as tetracycline, which suppress the growth of lactobacillus casei .

Use in Pregnancy:

Pregnancy teratogenic effects pregnancy category a folic acid is usually indicated in the treatment of megaloblastic anemias of pregnancy. folic acid requirements are markedly increased during pregnancy, and deficiency will result in fetal damage (see indications and usage ). studies in pregnant women have not shown that folic acid increases the risk of fetal abnormalities if administered during pregnancy. if the drug is used during pregnancy, the possibility of fetal harm appears remote. because studies cannot rule out the possibility of harm, however, folic acid should be used during pregnancy only if clearly needed.

Overdosage:

Overdosage except during pregnancy and lactation, folic acid should not be given in therapeutic doses greater than 0.4 mg daily until pernicious anemia has been ruled out. patients with pernicious anemia receiving more than 0.4 mg of folic acid daily who are inadequately treated with vitamin b 12 may show reversion of the hematologic parameters to normal, but neurologic manifestations due to vitamin b 12 deficiency will progress. doses of folic acid exceeding the recommended dietary allowance (rda) should not be included in multivitamin preparations; if therapeutic amounts are necessary, folic acid should be given separately.

Description:

Description folic acid, usp, n-[p-[[(2-amino-4- hydroxy-6-pteridinyl) methyl]- amino]benzoyl]-lglutamic acid, is a b complex vitamin containing a pteridine moiety linked by a methylene bridge to para -aminobenzoic acid, which is joined by a peptide linkage to glutamic acid. conjugates of folic acid, usp are present in a wide variety of foods, particularly liver, kidneys, yeast, and leafy green vegetables. commercially available folic acid, usp is prepared synthetically. folic acid, usp occurs as a yellow or yellowish-orange crystalline powder and is very slightly soluble in water and insoluble in alcohol. folic acid, usp is readily soluble in dilute solutions of alkali hydroxides and carbonates, and solutions of the drug may be prepared with the aid of sodium hydroxide or sodium carbonate, thereby forming the soluble sodium salt of folic acid, usp (sodium folate). aqueous solutions of folic acid, usp are heat sensitive and rapidly decompose in the presence of light and/or riboflavin; solutions should be stored in a cool place protected from light. the structural formula of folic acid, usp is as follows: each tablet, for oral administration, contains 1 mg folic acid, usp. folic acid tablets, usp 1 mg contain the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate and stearic acid. the structural formula of folic acid, usp is as follows:

Clinical Pharmacology:

Clinical pharmacology folic acid acts on megaloblastic bone marrow to produce a normoblastic marrow. in man, an exogenous source of folate is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. folic acid is the precursor of tetrahydrofolic acid, which is involved as a cofactor for transformylation reactions in the biosynthesis of purines and thymidylates of nucleic acids. impairment of thymidylate synthesis in patients with folic acid deficiency is thought to account for the defective deoxyribonucleic acid (dna) synthesis that leads to megaloblast formation and megaloblastic and macrocytic anemias. folic acid is absorbed rapidly from the small intestine, primarily from the proximal portion. naturally occurring conjugated folates are reduced enzymatically to folic acid in the gastrointestinal tract prior to absorption. folic acid appears in the plasma approximately 15 to 30 minutes after an oral dose; peak levels are generally reached within 1 hour. after
intravenous administration, the drug is rapidly cleared from the plasma. cerebrospinal fluid levels of folic acid are several times greater than serum levels of the drug. folic acid is metabolized in the liver to 7,8-dihydrofolic acid and eventually to 5,6,7,8- tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide (dpnh) and folate reductases. tetrahydrofolic acid is linked in the n 5 or n 10 positions with formyl, hydroxymethyl, methyl, or formimino groups. n 5 -formyltetrahydrofolic acid is leucovorin. tetrahydrofolic acid derivatives are distributed to all body tissues but are stored primarily in the liver. normal serum levels of total folate have been reported to be 5 to 15 ng/ml; normal cerebrospinal fluid levels are approximately 16 to 21 ng/ml. normal erythrocyte folate levels have been reported to range from 175 to 316 ng/ml. in general, folate serum levels below 5 ng/ml indicate folate deficiency, and levels below 2 ng/ml usually result in megaloblastic anemia. after a single oral dose of 100 mcg of folic acid in a limited number of normal adults, only a trace amount of the drug appeared in the urine. an oral dose of 5 mg in 1 study and a dose of 40 mcg/kg of body weight in another study resulted in approximately 50% of the dose appearing in the urine. after a single oral dose of 15 mg, up to 90% of the dose was recovered in the urine. a majority of the metabolic products appeared in the urine after 6 hours; excretion was generally complete within 24 hours. small amounts of orally administered folic acid have also been recovered in the feces. folic acid is also excreted in the milk of lactating mothers.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility long-term studies in animals to evaluate carcinogenic potential and studies to evaluate the mutagenic potential or effect on fertility have not been conducted.

How Supplied:

How supplied folic acid tablets, usp 1 mg, are round, yellow tablets debossed “n8” on one side and bisected on other side and supplied in bottles of 100 (ndc 10135-0182-01) and 1000 (ndc 10135-0182-10). dispense in well-closed container with child-resistant closure. store at controlled room temperature 20°-25°c (68°-77°f)[see usp controlled room temperature]. distributed by: marlex pharmaceuticals, inc. new castle, de 19720 rev. december 2016 5230/00

Package Label Principal Display Panel:

Principal display panel - 1mg ndc 67544-989 folic acid 1mg - rx only bottle label 1mg


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.